Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The discoveries of this year’s Nobel laureates in Physiology and Medicine have improved diagnostic and therapeutic strategies relying on oxygen sensing.
Translational cancer nanomedicine needs to increasingly exploit newly discovered tumour-targeting strategies as well as the further optimization of proven means to selectively increase the concentration of cytotoxic drugs in solid tumours.
Soft biomaterials for implantation in the body are increasingly designed to be functional for a finite time and to then disappear via degradation or resorption.
Modelling human tissues in microphysiologically relevant ‘chips’ will increasingly help to unravel mechanistic knowledge underlying disease, and might eventually accelerate the productivity of drug development and predict how individual patients will respond to specific drugs.
The development of imaging technology for the quantification of optical biomarkers of pathological processes should involve the validation of the biomarkers’ biological accuracy.
The simplicity and powerful capabilities of CRISPR have led to an explosion of genome-editing applications. Their continued development should be nurtured by scientific and legal environments that discourage and penalize irresponsible uses of the technology.
Implantable sensors and electrodes that take advantage of new materials, device designs and fabrication strategies enable new and improved biomedical applications.